Summary
To examine whether serum excitatory amino acid concentrations change with clozapine treatment and whether these changes correlate with improvement in negative symptoms, serum excitatory amino acids were measured and clinical scales administered in seven subjects with schizophrenia before and after switching from conventional neuroleptics to clozapine. Clozapine treatment was associated with increased serum glutamate and aspartate concentrations. Clinical improvement was negatively correlated with baseline glycine concentrations. These results support the hypothesis that clozapine acts at least in part by increasing glutamatergic activity.
Article PDF
Avoid common mistakes on your manuscript.
References
Alfredsson G, Wiesel FA (1990) Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenia patients. Psychopharmacology 101: 324–331
Alfredsson G, Wiesel FA, Tylec A (1988) Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers. Biol Psychiatry 23: 689–697
Alfredsson G, Wiesel FA, Lindberg M (1988) Glutamate and glutamine in cerebrospinal fluid and serum from healthy volunteers-analytical aspects. J Chromatogr 424: 378–384
Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271: 787–794
Corbett R, Camacho R, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology 120: 67–74
Coyle JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 3: 241–253
Daly DA, Moghaddam B (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152: 61–64
Farber NB, Price MT, Labruyere J, Nemnich J, St. Peter H, Wozniak DF, Olney JW (1993) Antipsychotic drugs blocks phencyclidine induced neurotoxicity. Biol Psychiatry 34: 119–121
Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152: 1213–1215
Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996) D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153: 1628–1630
Kim JS, Kornhuber Fffl, Schmid-Burgk W, Holzmuller B (1980) Low cerebrospinal glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379–382
Korpi ER, Kaufmann CA, Marnela KM, Weinberger DR (1987) Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res 20: 337–345
Lang A, Soosar A, Harro J (1992) The involvement of sigma and phencyclidine receptors in the action of antipsychotic drugs. Pharmacol Toxicol 71: 132–138
McGale EHF, Pye IF, Stonier C, Hutchinson EC, Aber GM (1977) Studies of the interrelationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals. J Neurochem 29: 291–297
Olney JW, Farber NB (1994) Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry 55: 43–46
Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998–1007
Tiedtke PI, Bischoff C, Schmidt WJ (1990) MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm 81: 173–182
Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990) D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510: 158–160
Yamamoto BK, Pehek EA, Meltzer HY (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55: 8–14
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Evins, A.E., Amico, E.T., Shih, V. et al. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J. Neural Transmission 104, 761–766 (1997). https://doi.org/10.1007/BF01291892
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01291892